• Home
  •  / Mirati Therapeutics

Mirati Therapeutics

OverviewSuggest Edit

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of oncology products including candidates intended to treat specific genetic and epigenetic drivers of cancer in selected subsets of cancer patients with unmet needs. The Company's clinical pipeline consists of three product candidates: glesatinib, sitravatinib and mocetinostat. Both glesatinib and sitravatinib are orally-bioavailable, spectrum-selective kinase inhibitors with distinct target profiles that are in development for the treatment of patients with NSCLC and other solid tumors.

TypePublic
Founded2013
HQSan Diego, USMap
Websitemirati.com
View Jobs (8)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)111(+77%)
Job Openings8
Revenue (FY, 2019)$3.3 M(-74%)
Share Price (Sept 2020)$161.1
Cybersecurity ratingAMore

Key People/Management at Mirati Therapeutics

Charles M. Baum

Charles M. Baum

Director, President and Chief Executive Officer
Julie M. Cherrington

Julie M. Cherrington

Director
Allen Albright

Allen Albright

Vice President, Regulatory Affairs and Quality Assurance
Aaron I. Davis

Aaron I. Davis

Director
Ryan Asay

Ryan Asay

Vice President, Corporate Affairs
Henry J. Fuchs

Henry J. Fuchs

Director
Show more

Mirati Therapeutics Office Locations

Mirati Therapeutics has an office in San Diego
San Diego, US (HQ)
9393 Towne Centre Dr #200
Show all (1)

Mirati Therapeutics Financials and Metrics

Mirati Therapeutics Revenue

Mirati Therapeutics's revenue was reported to be $3.34 m in FY, 2019
USD

Net income (Q2, 2020)

(82.9m)

EBIT (Q2, 2020)

(84.9m)

Market capitalization (18-Sept-2020)

7.2b

Closing stock price (18-Sept-2020)

161.1

Cash (30-Jun-2020)

131.7m
Mirati Therapeutics's current market capitalization is $7.2 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

12.9m3.3m

General and administrative expense

11.1m12.7m15.8m15.3m13.5m21.7m42.6m

R&D expense

19.8m26.1m49.0m68.5m58.1m93.9m182.9m

Operating expense total

32.0m39.1m64.7m83.8m71.5m115.6m225.4m
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

9.5m1.2m577.0k988.0k267.0k

General and administrative expense

2.4m3.7m2.4m2.9m3.5m3.8m4.2m4.2m4.1m3.8m3.5m3.7m3.7m3.1m5.2m4.8m5.3m9.8m9.9m10.7m18.0m19.8m

R&D expense

4.5m5.5m5.2m7.2m7.0m8.2m11.3m14.6m18.0m18.4m16.1m14.4m15.0m13.5m19.7m23.8m23.6m34.2m38.3m47.4m71.7m65.1m

Operating expense total

6.9m9.2m8.0m10.1m10.5m12.0m15.5m18.7m22.1m22.2m19.6m18.1m18.6m16.6m24.8m28.7m28.9m44.0m48.2m58.0m89.8m84.9m
show all
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

14.2m6.6m49.5m22.4m107.7m32.7m46.5m

Accounts Receivable

Prepaid Expenses

2.1m3.4m3.1m4.9m3.9m9.4m

Inventories

Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

9.7m7.6m8.3m8.5m4.9m14.3m13.4m109.9m34.6m24.5m19.8m29.8m20.0m20.8m20.6m106.0m116.7m74.6m252.1m91.9m204.5m131.7m

Accounts Receivable

66.0k

Prepaid Expenses

1.8m1.5m2.7m1.7m2.6m3.2m2.0m3.0m2.2m1.7m2.5m2.5m4.4m4.4m4.4m3.4m3.5m5.4m10.2m10.4m9.5m8.3m

Current Assets

22.4m17.0m56.0m49.2m40.3m71.2m60.9m141.0m109.9m93.0m75.5m107.9m92.3m79.4m153.1m263.6m246.1m306.4m495.7m464.6m704.8m654.0m
show all
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(52.9m)(43.7m)(64.5m)(83.1m)(70.4m)(98.4m)(213.3m)

Depreciation and Amortization

171.0k199.0k212.0k180.0k184.0k175.0k249.0k

Accounts Payable

(68.0k)151.0k4.4m5.2m(1.3m)12.9m23.0m

Cash From Operating Activities

(29.5m)(32.7m)(50.7m)(68.0m)(64.7m)(70.1m)(147.7m)
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(12.2m)(41.6m)(13.7m)(24.7m)(33.3m)(11.9m)(27.4m)(46.1m)(21.9m)(44.0m)(63.4m)(17.8m)(36.2m)(52.5m)(14.7m)(42.6m)(70.1m)(40.9m)(86.6m)(140.9m)(86.7m)(169.5m)

Depreciation and Amortization

64.0k105.0k78.0k116.0k154.0k44.0k100.0k153.0k58.0k100.0k45.0k41.0k131.0k44.0k99.0k126.0k253.0k

Accounts Payable

(756.0k)1.3m(1.3m)649.0k111.0k(482.0k)1.7m4.4m1.0m4.0m3.8m(3.5m)(3.1m)(3.3m)2.7m4.9m8.6m(1.1m)2.1m9.3m6.9m8.8m

Cash From Operating Activities

(16.5m)(21.7m)(8.8m)(14.5m)(24.2m)(9.8m)(18.8m)(34.7m)(17.0m)(33.6m)(51.9m)(18.2m)(35.8m)(50.9m)(7.9m)(29.1m)(49.3m)(34.5m)(72.9m)(105.8m)(59.0m)(118.3m)
show all
USDQ2, 2013

Financial Leverage

3.7 x
Show all financial metrics

Mirati Therapeutics Operating Metrics

FY, 2016

Patents Issued

32

Patents Pending

1
Show all operating metrics

Mirati Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

Learn more about about our premium products
SecurityScorecard logo

Mirati Therapeutics Online and Social Media Presence

Mirati Therapeutics's Trends

Embed Graph

Mirati Therapeutics News and Updates

February 15, 2020

Mirati Therapeutics Announces Initial Data In Renal Cell Carcinoma From Ongoing Investigator Sponsored Clinical Trial Of Sitravatinib In Combination With Nivolumab At The 2020 ASCO Genitourinary Cancers Syposium

SAN DIEGO, Feb. 15, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the presentation of initial data from an ongoing investigator sponsored Phase 1/2 clinical trial of sitravatinib in combination with nivolumab...
November 09, 2019

Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th Annual Meeting

SAN DIEGO, Nov. 9, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the presentation of initial data from its ongoing Phase 2 clinical trial of sitravatinib in combination with nivolumab (OPDIVO®) in metastatic...
May 30, 2019

Mirati Therapeutics To Present At Jefferies 2019 Global Healthcare Conference

SAN DIEGO, May 30, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will present at the Jefferies Annual Global Healthcare Conference in New York on Thursday, June 6th at 2:00 p.m. ET/ 11:00 a.m. PT. Charles M. Baum, M.D., Ph.D.,...
April 01, 2019

Mirati Therapeutics To Present At The H.C. Wainwright & Co. Global Life Sciences Conference

SAN DIEGO, April 1, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the H.C. Wainwright & Co. Global Life Sciences Conference in London, England on Monday, April 8th at 11:30am BST/6:30am ET/3:30am PT. Christopher...
March 05, 2019

Mirati Therapeutics To Present At Upcoming Healthcare Conferences

SAN DIEGO, March 5, 2019 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at two upcoming healthcare conferences. Cowen 39th Annual Healthcare Conference in Boston on Tuesday, March 12th at 11:20 a.m. ET/ 8:20 a.m. PT. Oppenheimer 29th...
February 07, 2019

Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day

SAN DIEGO, Feb. 7, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in the Guggenheim Healthcare Talks Idea Forum & Oncology Day in New York on Thursday, February 14th at 11:00 a.m. ET/ 8:00 a.m. PT. Chris...
Show more

Mirati Therapeutics Blogs

January 15, 2019

Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor

Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor Content Import Tue, 01/15/2019 - 16:25 Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor …
January 07, 2019

Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®)

Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®) Content Import Mon, 01/07/2019 - 08:38 Mirati Announces Clinical Collaboration With Bristol-Myers S…
September 24, 2018

Michael Schmidt, Ph. D. - Guggenheim

Michael Schmidt, Ph. D. - Guggenheim Janice.Nispero… Mon, 09/24/2018 - 17:45 Michael Schmidt, Ph. D. Guggenheim
September 14, 2018

Edward White - Wainwright

Edward White - Wainwright Janice.Nispero… Fri, 09/14/2018 - 19:45 Edward White Wainwright
September 14, 2018

Leah Cann, Ph. D - Oppenheimer

Leah Cann, Ph. D - Oppenheimer Janice.Nispero… Fri, 09/14/2018 - 19:41 Leah Cann, Ph. D Oppenheimer
September 14, 2018

Gena Wang, Ph.D. - Barclays

Gena Wang, Ph.D. - Barclays Janice.Nispero… Fri, 09/14/2018 - 19:37 Gena Wang, Ph.D. Barclays
Show more

 Mirati Therapeutics Frequently Asked Questions

  • When was Mirati Therapeutics founded?

    Mirati Therapeutics was founded in 2013.

  • Who are Mirati Therapeutics key executives?

    Mirati Therapeutics's key executives are Charles M. Baum, Julie M. Cherrington and Allen Albright.

  • How many employees does Mirati Therapeutics have?

    Mirati Therapeutics has 111 employees.

  • What is Mirati Therapeutics revenue?

    Latest Mirati Therapeutics annual revenue is $3.3 m.

  • What is Mirati Therapeutics revenue per employee?

    Latest Mirati Therapeutics revenue per employee is $30 k.

  • Who are Mirati Therapeutics competitors?

    Competitors of Mirati Therapeutics include OncoStem Diagnostics, Infinity Pharmaceuticals and Merrimack Pharmaceuticals.

  • Where is Mirati Therapeutics headquarters?

    Mirati Therapeutics headquarters is located at 9393 Towne Centre Dr #200, San Diego.

  • Where are Mirati Therapeutics offices?

    Mirati Therapeutics has an office in San Diego.

  • How many offices does Mirati Therapeutics have?

    Mirati Therapeutics has 1 office.